CAR-T 细胞疗法联合自体干细胞移植改善了复发/难治性弥漫大 B 细胞淋巴瘤患者的无进展生存期：一项单中心、回顾性、队列研究

Autologous hematopoietic stem cell transplantation (ASCT) and chimeric antigen receptor T-cell therapy (CART) are salvage therapies that are utilised for treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

However, whether the combination therapy of ASCT and CART (ASCT-CART) can improve the survival of R/R DLBCL remains unknown.

Overall, 67 R/R DLBCL patients were included, among which 21 patients underwent ASCT-CART therapy and 46 patients underwent ASCT therapy. The median number of mononuclear cells numbers that were infused in the ASCT-CART and ASCT groups was 4. 71 × 10 8 /kg and 5. 36 × 10 8 /kg, respectively (p = 0. 469).

The median number of CD34 + cell numbers that were infused in the ASCT-CART and ASCT groups was 2. 41 × 10 6 /kg and 3. 05 × 10 6 /kg, respectively (p = 0. 663). The median number of CART cells that were infused was 2. 63 × 10 6 /kg with a median transduction rate of 59. 83%. The objective response rates to ASCT-CART and ASCT therapy were 90% and 89%, respectively (p = 1. 000).

However, the ASCT-CART group showed higher complete remission (CR) rates than the ASCT group (71% vs. 33%; p = 0. 003). The ASCT-CART group demonstrated superior 3 year progression-free survival (PFS) (80% vs. 44%; p = 0. 036) and lower 3 year relapse/progression rate (15% vs. 56%; p = 0. 015) compared to the ASCT group.

However, the 3 year overall survival results indicated that there were no differences between the two groups (80% vs. 69%; p = 0. 545). For R/R DLBCL patients, ASCT-CART therapy is associated with higher CR rate, better PFS, and lower relapse/progression rate. These data support that ASCT-CART therapy can be used as a salvage therapy for R/R DLBCL patients.